Video capsules
Treatment of COVID-19 with Evusheld: A Canadian Perspective on the TACKLE Trial
Dr. Zain Chagla presents a summary of the TACKLE trial and a Canadian perspective on Evusheld for the treatment of COVID-19.
17 minutes
Urothelial Carcinoma: EV-301 Update from ASCO 2022
Dr. Nimira Alimohamed discusses updates on the treatment of urothelial carcinoma, focusing on data from the EV-301 trial presented at the ASCO 2022 virtual meeting.
9 minutes
Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022 (French)
Dr. Jean-Francois Larouche discusses updates on the treatment of cHL, focusing on data from the ECHELON-1 trial presented at the ASCO 2022 virtual meeting. (In French)
10 minutes
Hodgkin Lymphoma: ECHELON-1 Update from ASCO 2022
Dr. John Kuruvilla discusses updates on the treatment of cHL, focusing on data from the ECHELON-1 trial presented at the ASCO 2022 virtual meeting.
18 minutes
Highlights from ASCO/EHA 2021: Updates in CLL
Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASCO/EHA 2021 virtual meetings.
24 minutes
ASCO/EHA 2021: traitement de la LLC
Le Dr Stephane Doucet discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASCO et EHA de 2021.
40 minutes
Highlights from ASH 2021: Updates in CLL
Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASH 2021 meeting.
22 minutes
ASH 2021: traitement de la LLC
Dr. Michel Pavic, Onco-hématologue a l’Estrie-CHUS, discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASH de 2021.
27 minutes
CGP Report: Recommendations for Funders
Dr. Sandeep Sehdev discusses recommendations for funding comprehensive genomic profiling for payers in Canada. The full CGP report is available at: https://www.impactmedicom.com/publications/reports. Funding for the CGP report was provided by AstraZeneca, Roche, and Illumina.
35 minutes
ASH 2020: Updates on CLL
Dr. Carolyn Owen discusses updates on the treatment of CLL from the ASH 2020 virtual meeting.
18 minutes
ASH 2020: traitement de la LLC
La Dre Silvy Lachance discute des principales études sur la LLC qui ont été présentées au congrès virtuel de l’ASH de 2020.
36 minutes
BTK Inhibitors for the Frontline Treatment of CLL
Dr. Laurie Sehn discusses the management of BTK-related toxicities, based on a recently published paper in Current Oncology by Dr. Laurie Sehn, Dr. Andrew Aw & Dr. Sue Robinson.
28 minutes
Les inhibiteurs de la BTK pour le traitement de première intention de la LLC Présentation
La Dre Inès Chamakhi discute de la prise en charge des toxicités liées aux inhibiteurs de la BTK d’après un article récemment publié dans la revue Current Oncology par la Dre Laurie Sehn , le Dr Andrew Aw et la Dre Sue Robinson.
20 minutes
Treatment of CLL during COVID-19
Dr. Laurie Sehn discusses the treatment of CLL during the coronavirus pandemic, based on a recently published paper by Dr. Laurie Sehn, Dr. Philip Kuruvilla, and Dr. Julie Stakiw. The full paper can be found here: https://www.current-oncology.com/inde....
20 minutes
Prise en charge de la LLC au Canada pendant la pandémie de COVID-19
Dr Michel Pavic discute du traitement de la LLC à l’ère de la pandémie de Covid 19, d’après les résultats d’un article publié récemment dans la revue Current Oncology (Dre Laurie Sehn, Dr Philip Kuruvilla et Dre Julie Stakiw).
20 minutes
ASCO 2020: CLL Updates
Dr. Mona Shafey presents key updates on the treatment of chronic lymphocytic leukemia from the ASCO 2020 virtual Meeting.
32 minutes
ENGLISH: NGS Guidelines
Dr. Stephen Yip, Director of the Cancer Genetics & Genomics Lab at BC Cancer in Vancouver, British Columbia, presents a summary of the first Canadian guidelines on Next Generation Sequencing (NGS). The published guidelines can be found in the April issue of Current Oncology.
2 hours
FRENCH: NGS Guidelines
Dr. Patrice Desmeules, Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Québec, QC presents a summary of the recently published Canadian guidelines on next generation sequencing (NGS).
1 hr 40 minutes
ASH 2019: CLL Updates
Dr. Versha Banerji Discusses Practice-Changing Studies in Treatment-Naive CLL.
23 minutes
**Funding provided by AstraZeneca, Janssen, Seagen Canada
Tel. 416-434-8923
Email. info@impactmedicom.com